| United States Patent | RE40,812 |
| Stern | June 30, 2009 |
Nasal calcitonin formulation
Abstract
.[.A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about to about 50 mM, said composition being in a form table for nasal administration..]. .Iadd.A liquid pharmaceutical composition is provided for nasal administration of calcitonin or an acid addition salt thereof. The nasal pharmaceutical formulations contain a component selected from the group consisting of citric acid, citric acid salt and a combination thereof..Iaddend.
| Inventors: | Stern; William (Tenafly, NJ) |
| Assignee: |
Unigene Laboratories Inc.
(Boonton,
NJ)
|
| Appl. No.: | 10/774,358 |
| Filed: | February 5, 2004 |
| Application Number | Filing Date | Patent Number | Issue Date | ||
| 60180241 | Feb., 2000 | ||||
| Reissue of: | 09776537 | Feb., 2001 | 06440392 | Aug., 2002 | |
| Current U.S. Class: | 424/434 ; 424/45; 424/455; 514/1.1 |
| Current International Class: | A61K 9/12 (20060101); A61K 38/23 (20060101); A61K 9/00 (20060101) |
| Field of Search: | 424/43,45,434,455 514/2,3,12,13 530/324,307 |
| 4151276 | April 1979 | Caulin et al. |
| 4690952 | September 1987 | Kagatani et al. |
| 4788221 | November 1988 | Kagatani et al. |
| 4845080 | July 1989 | Fischer |
| 4900730 | February 1990 | Miyauchi |
| 5023252 | June 1991 | Hseih |
| 5026825 | June 1991 | Grebow et al. |
| 5059587 | October 1991 | Yamamoto et al. |
| 5124315 | June 1992 | Ceschel et al. |
| 5183802 | February 1993 | Aliverti et al. |
| 5234906 | August 1993 | Young et al. |
| 5279836 | January 1994 | Nicolaus |
| 5281580 | January 1994 | Yamamoto et al. |
| 5310727 | May 1994 | Lattanzi et al. |
| 5496801 | March 1996 | Holthuis et al. |
| 5514365 | May 1996 | Mardente et al. |
| 5534496 | July 1996 | Lee et al. |
| 5536508 | July 1996 | Canal et al. |
| 5571788 | November 1996 | Arvinte et al. |
| 5593962 | January 1997 | Arvinte et al. |
| 5637309 | June 1997 | Tajima et al. |
| 5654000 | August 1997 | Poli et al. |
| 5665700 | September 1997 | Cho et al. |
| 5693608 | December 1997 | Bechgaard et al. |
| 5700486 | December 1997 | Canal et al. |
| 5714477 | February 1998 | Einarsson |
| 5719122 | February 1998 | Chiodini et al. |
| 5725871 | March 1998 | Illum |
| 5726154 | March 1998 | Baudys et al. |
| 5733569 | March 1998 | Azria et al. |
| 5733572 | March 1998 | Unger et al. |
| 5759565 | June 1998 | Azria et al. |
| 5759566 | June 1998 | Poli et al. |
| 5776886 | July 1998 | Inamoto et al. |
| 5858391 | January 1999 | Cuca et al. |
| 5912014 | June 1999 | Stern et al. |
| 5938654 | August 1999 | Wong et al. |
| 5968899 | October 1999 | Sekine et al. |
| 6008189 | December 1999 | Inamoto et al. |
| 6017538 | January 2000 | Druilhe et al. |
| 6086918 | July 2000 | Stern et al. |
| 6087338 | July 2000 | Veronesi et al. |
| 6107277 | August 2000 | Veronesi et al. |
| 6149893 | November 2000 | Mardente et al. |
| 6153582 | November 2000 | Skelnik |
| 6348207 | February 2002 | Milstein et al. |
| 6440392 | August 2002 | Stern |
| 6440446 | August 2002 | Yoshizane et al. |
| 6447785 | September 2002 | Donovan |
| 6509006 | January 2003 | Platz et al. |
| 0 115 627 | Aug., 1984 | EP | |||
| 0 327 756 | Aug., 1989 | EP | |||
| 0 358 234 | Mar., 1990 | EP | |||
| 0 371 010 | May., 1990 | EP | |||
| 0 418 697 | Mar., 1991 | EP | |||
| 0 489 217 | Jun., 1992 | EP | |||
| 0 726 075 | Aug., 1996 | EP | |||
| 0 809 512 | Dec., 1997 | EP | |||
| 2092002 | Aug., 1982 | GB | |||
| 05 078258 | Mar., 1993 | JP | |||
Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories Inc., et al. v. Apotex Inc., et al., Civil Action No. 06-CV-5571--RPP-THK, EFC Case (S.D.N.Y.) Sep. 20, 2006. cited by other . Dua et al., International Journal of Pharmaceutics 147, 1997, pp. 233-242 "The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits." cited by other . P. Graf et al., Clin., Exp. Allergy, vol. 25:395-400; 1995 "Benzalkoium chloride in a decongestant nasal spray aggravates Rhinitis medicamentosa in healthy volunteers". cited by other . H. Hallen et al., Clin. Exp. Allergy, vol. 25:401-405; 1995 "Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers". cited by other . Berg et al., Laryngoscope 104:1153-1158; 1994 "The Effect of Decongestive Nosedrops on Human Respiratory Mucosa In Vitro". cited by other . P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992 "The effects of calcitonin nsala preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test". cited by other . Remington, The Science and Practice of Pharmacy, 20.sup.th Edition, Philadelphia (USA) Jan. 2000, Chapter 47, pp. 922-923. cited by other . Repertorio Farmaceutico Italiano, REFI 4a Edizione (REFI 4.sup.th Edition), 1990, p. A 212, (Calcitonina Spray Nasale Arnmour, and p. A223 "Carbicalcin Spray", Farmindustria, Associazione dell'Idustria Farmaceutica (National Association of the Pharmaceutical Industry)--CEDOF Editor, 1990. cited by other . The Merck Index, 13.sup.th Edition, 2001, p. 3576. cited by other . Physicians' Desk Reference-PDR 53 Edition 1999, pp. 2057-2059. cited by other . Romeijn S.G., et al., Int. J. Pharm.,1996,135/1-2 (137-145), "The Effect of Nasal Drug Formulations on Ciliary Beating in vitro", abstract. cited by other . Schipper N.G.M., et al., Calcif. Tissue Int.,1995, 56/4 (280-282) "Methylated (beta)-cyclodextrins are Able to Improve the Nasal Absorption of Salmon Calcitonin", abstract. cited by other . Marttin E., Pharm. Res., May 1997, 14 (5): 631-7, "Confocal Laser Scanning Microscopic Visualization of the Transport of Dextrans After Nasal Administration to Rats: Effects of Absorption Enhancers", abstract. cited by other . Abe K., et al., Chem. Pharm. Bull (Tokyo) Dec. 1995; 43 (12): 2232-7, "Enhanced Nasal Delivery of Luteinizing Hormone Releasing Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-beta-cyclodextrin", abstract. cited by other . Kagatani S., et al., Pharm. Res. 1996 13/5 (739-743), "Enhancement of Nasal Salmon Calcitonin Absorption by Lauroyclarnitine Chloride in Rats", abstract. cited by other . Morimoto K., et al., J. Pharma. Pharmacol. 1985 37/2 (134-136) "Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel", abstract. cited by other . Martin E., et al., Pharm Res May 1997; 14(5) : 631-7, "Confocal laser scanning microscopic visualization of the transport of Dextrans after Nasal Administration to Rats: Effects of Absorption Enhancers", abstract. cited by other . Kurosaki Y., et al., J. Pharmacobiodyn Dec. 1988; 11 (12) : 824-32, "Application of Propranolol to the Keratinized Oral Mucosa: Avoidance of First-Pass Elimination and the Use of 1-Dodecylazacycloheptan-2-one (Azone) as an Absorption Enhancer of Bioadhesive Film-Dosage Form", abstract. cited by other . Okamoto H., et al., J. Pharm. Pharmacol Jul. 1987; 39 (7) : 531-4, "Enhanced penetration of mitromycin C through hairless mouse and rats skin by enhancers with terpene moieties", abstract. cited by other . Sugibayashi K., et al., J. Pharm. Pharmacol Aug. 1985; 37 (8) : 578-80, "Effect of the Absorption Enhancer, Azone, on the Transport of 5-Fluorouracil Across Hairless Rat Skin", abstract. cited by other . Vermehren C:, et al., Drug Metab Dispos Sep. 1997; 25 (9): 1083-8, "Absorption and Metabolism of the Absorption Enhancer Didecanoylphosphatidylcholine in Rabbit Nasal Epithelium in vivo", abstract. cited by other . Jacobs M.A., et al., Diabetes Nov. 1993; 41 (11) : 1649-55, "The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers", abstract. cited by other . Schipper N.G., et al., Pharm Res Nov. 1996; 13 (11) : 1686-92, "Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells", abstract. cited by other . Pillion D.J., et al., J. Pharm. Sci. Nov. 1995; 84 (11) : 1276-9, "DS-1, A Modified Quillaja Saponin, Enhances Ocula and Nasal Absorption of Insulin", abstract. cited by other . Agerholm C., et al., J. Pharm. Sci. Dec. 1994; 83 (12) : 1706-11, "Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoyl-L-alpha-phosphatidylcholine and alpha-cyclodextrin in Rabbits", abstract. cited by other . Critchley H., et al., J. Pharm Pharmacol Aug. 1994; 46 (8) : 651-6, "Nasal Absorption of Desmpressin in Rats and Sheep. Effect of A Bioadhesive Microsphere Delivery System", abstract. cited by other . Santus G., et al., Farmaco Dec. 1993; 48 (12) : 1709-33, "Nasal Formulations of Ketorolac Tromethamine: Technological Evaluation--Bioavailability and Tolerability in Rabbits", abstract. cited by other . Donovan M.D., et al., Pharm. Res. Aug. 1990; 7 (8) : 808-15, "The Molecular Weight Dependence of Nasal Absorption: the Effect of Absorption Enhancers", abstract. cited by other . Pontiroli A.E., et al., Eur J Clin Pharmacol 1989; 37 (4) : 427-30, "Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: A Comparison of Powders and Spray Solutions and of Different Enhancing Agents", abstract. cited by other . Shao Z., et al., Pharm Res Sep. 1992: 9 (9) : 1157-63, "Cyclodextrins as Nasal Absorption Promoters of Insulin : Mechanistic Evaluations", abstract. cited by other . Sarkar M.A., Pharm Res Jan. 1992; 9 (1) : 1-9, "Drug Metabolism in the Nasal Mucosa", abstract. cited by other . Morimoto K., et al., Pharm Res Sep. 1991; 8 (9) : 1175-9, "Effects of Proteolytic Enzyme Inhibitors on the Nasal Absorption of Vasoppressin and an Analogue", abstract. cited by other . Hosoya K., et al., Biol Pharm Bull Feb. 1994; 17 (2) : 316-22, "Evaluation of Enhancers to Increase Nasal Absorption Using Ussing Chamber Technique", abstract. cited by other . Tengamnuay P., et al., Pharm Res Apr. 1990; 7 (4) : 370-5, "Bile Salt-Fatty Acid Mixed Micelles as Nasal Absorption Promoters of Peptides. II. In vivo Nasal Absorption of Insulin in Rats and Effects of Mixed Micelles on the Morphological Integrity of the Nasal Mucosa", abstract. cited by other . Patent family search for EP 0358234 (equiv. USP 5,026,825),1/34/1 Dialog(R) File 351:Derwent abstract, (008189979, "Intranasal calcitonin formulations--contg. Delta-amino-laevulinic acid for enhanced bioavailability" (priority application 1988). cited by other . Patent family search for GB 2212062 (equiv. EP 0327756), 2/34/1 Dialog(R) File 351: Derwent abstract, 007943804, "Pharmaceutical Calcitonin--contg. for nasal glycyrrihizinate to enhance mucosal membrane absorption, esp. for nasal administration" (priority application 1987). cited by other . Caspar W.R., et al. , Drug & Cosmetic Industry, vol. 156; No. 1; p. 46, "New Ways of Enhancing the Delivery of Skin Care Ingredients", Jan. 1995. cited by other . Ratafia, Manny, et al. M&M Medical Marketing & Media, vol. 24; No. 11, p. 10; "Drug Delivery: the Key to Biotechnology Markets", Oct. 1, 1989. cited by other . Biotechnology Newswatch, vol. 9, No. 12; p. 1, "Two-nasally delivered CalBio hormones pass initial clinicals", Jun. 19, 1989. cited by other . Observations on European Patent Application No. EP 1251867 (third party observations) dated Jan. 17, 2003. cited by other . European Search Report dated Oct. 10, 2004. cited by other . Database WPI, Section Ch, Week 199317, Derwent Publications Ltd., London, GB; Class B04, AN 1993-140304, XP002300282 & JP 05 078258 A (Suntory) Mar. 30, 1993. cited by other . Apotex Notice Letter--Jun. 1, 2006. cited by other . Complaint by Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., 06-cv-5571-RPP-THK (EFC Case)--U.S. District Court for the Southern District of New York. cited by other . Second Declaration of Inventor William Stern Under 37 CFR .sctn. 1.132 dated Sep. 7, 2007. cited by other . Amended Answer to Complaint for Patent Infringement, Affirmative Defenses and Counterclaims, Unigene Laboratories, Inc. et at. v. Apotex, Inc., et al., Civil Action No. 06-CV-5571--RPP-THK EFC Case (S.D.N.Y.), May 8, 2007. cited by other . Office Action from the European Patent Office concerning European Application Serial No. 01 908 769.1-1219 dated Feb. 2, 2007. cited by other . Third Declaration of inventor William Stern under 37 C.F.R. .sctn. 1.132, with Exhibits. cited by other . Jul. 14, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP). cited by other . Jul. 15, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP). cited by other . Jul. 16, 2008 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 Civ. 5571 (RPP). cited by other . Nov. 6, 2007 Hearing Transcript of Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). cited by other . Feb. 4, 2008 Opinion and Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). cited by other . Feb. 20, 2008 Defendants' Notice of Motion in Support of Defendants' Motion For Reconsideration of the Feb. 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). cited by other . Feb. 20, 2008 Memorandum of Law in Support of Defendants' Motion for Reconsideration of the of the Feb. 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). cited by other . Plaintiffs' Memorandum of Law in Opposition to Defendants' Motion for Reconsideration of the Feb. 4, 2008 Order Regarding Defendants' Motion to Compel Discovery in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). cited by other . Feb. 28, 2008 Order issued in Unigene Laboratories, Inc., et al., v. Apotex, Inc., et al., 06 CIV 5571 (RPP). cited by other . Armyn P. Sayani, et al. "Systemic Delivery of Peptides and Proteins Across Absorptive Mucoase", Critical Reviews in Therapeutic Drug Carrier Systems, 13 (1&2):85-184 at pp. 106,127,128,144,158,160 (1996). cited by other . Bell, L.N., "Peptide stability in solids and solutions", Biotechnology Progress 13:342-346. (1997). cited by other . Lee, K.C. et al., "Degradation of synthetic salmon calcitonin in aqueous solutions", Pharm. Res. 9:1521-1523. (1992). cited by other . Windisch, V. et al., "Degradation Pathways of Salmon Calcitonin in Aqueous Solution", J. Pharm. Sci., 86, 359-364. (1997). cited by other . M. Gibson, Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commerical Dosage Form, p. 479 and Chapter 13, Aqueous Nasal Dosage Forms, Ed., Taylor & Francis. (2001). cited by other . A.E. Pontiroli, et al., Intranasal calcitonin and plasma calcium concentrations in normal subjects, British Medical Journal, Clinical Research ed., 290:1390-1391. (1985). cited by other . P. Nykanen, et al., "Organic acids as excipients in matrix granules for colon-specific drug delivery", Int. J. Pharm. 184:251-261. (1999). cited by other . N.R. Anderson, et al., "Quantitative evaluation of pharmaceutical effervescent systems II: Stability monitoring by reactivity and porosity measurements", Journal of Pharmaceutical Sciences, 71:7-13. (1982). cited by other . Li, Y., et al., "Effect of a conjugated bile salt on the pulmonary absorption of insulin in rats", Eur. J. Pharm. Biopharm, 39:216-21. (1993). cited by other . Kobayashi, S., et al., "Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats", Pharmaceutical Research, 13:80-83. (1996). cited by other . Physicians' Desk Reference 52.sup.nd Edition at 1880-1881 (1998). cited by other . R.C. Henrikson, et al., Histology, Lippincott Williams and Wilkins pp. 311-321 at 314 (1997). cited by other . Pharmaceutical Dosage Forms and Drug Delivery Systems, 7.sup.th Edition, Lippincott Williams & Wilkins, pp. 77-81 (1999). cited by other . Wade & Weller, Handbook of Pharmaceutical Excipients, 2.sup.nd Edition, American Pharmaceutical Association and the Pharmaceutical Press, pp. 34-37, 122-125, 339-345, 439-440 (1994). cited by other . D. Voet and J.G. Voet, Biochemistry, 2.sup.nd Edition, John Wiley & Sons, New York, pp. 538-541 (1995). cited by other . V. Agarwal et al., "Recent trends in drug delivery systems: intranasal drug delivery", Indian Journal of Experimental Biology, 37:6-16. (1999). cited by other . D. Harris, et al., "Bioadhesive polymers in peptide drug delivery", Biomaterials, 11:652-658. (1990). cited by other . M.J. Cho., et al., "Citric acid as an adjuvant for transepithelial transport" International Journal of Pharmaceutics, 52:79-81. (1989). cited by other . Hayashi, et al., "Physiological mechanism for enhancement of paracellular drug transport", Journal of Controlled Release, 62: 141-148. (1999). cited by other . Tyler-Cross et al., "Effects of amino acids sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides", Journal of Biological Chemistry 266:22549-22556. (1991). cited by other . Reubsaet et al., "Degradation kinetics of antagonist [Arg.sup.6, D-Trp.sup.7,9, MePhe.sup.8]-substance P{6-11} in aqueous solutions", Analytical Biochemistry 227:334-341. (1995). cited by other . Declaration of Ashim K. Mitra, Ph.D. Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. cited by other . Declaration of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. cited by other . Declaration of Michael Sofocleous dated Oct. 13, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. cited by other . Declaration of Professor Robert S. Langer Regarding Invalidity of U.S. Patent 6,440,392 dated Oct. 14, 2008, in Unigene Laboratories, Inc. et al. v. Apotex, Inc. et al., 06-CV-5571-RPP-THK. cited by other . Opinion and Order dated Aug. 28, 2008, in Unigene Laboratories, Inc., et al. v. Apotex, Inc., et al., 06, CV 5571 (RPP). cited by other . Rebuttal Declaration and Expert Report of Professor Alexander M. Klibanov Regarding Invalidity of U.S. Pat. No. 6,440,392. cited by other . Rebuttal Declaration and Expert Report of Ashim K. Mitra, Ph.D. cited by other . Rebuttal Declaration and Expert Report of Professor Robert S. Langer Regarding Invalidity of U.S. Pat. No. 6,440,392. cited by other . Rebuttal Declaration and Expert Report of Michael Sofocleous. cited by other . M. Weiner and I. Leonard Bernstein, 1989, Adverse Reactions to Drug Formulation Agents, A Handbook of Excipients, Marcel Dekker, Inc. 1989, pp. 361-363 and 390-391. cited by other . Stephen G. Farmer and Douglas W.P. Hay, Editors, The Airway Epithelium: Physiology, Pathophysiology and Pharmacology 1991: 3-39, Marcel Dekker, Inc. cited by other . Akwete Lex Adjei and Pramod K. Gupta, Editors, Inhalation Delivery of Therapeutic Peptides and Proteins, 1997:493-514, Marcel Dekker, Inc. cited by other . Akers and DeFelippis, Pharmaceutical Formulation Development of Peptides and Proteins, (published 2000), Sven Frokjaer and Lars Hovgaard, Editors Pharmaceutical Formulation Development of Peptides and Proteins, pp. 145-177, CRC Press 2000. cited by other . Expert Report of Henry Kwan, Ph.D. Regarding Validity of U.S. Pat. No. 6,440,392, dated Dec. 2, 2008, pp. 1-182. cited by other . Expert Report of Dr. Robert P. Raymond, Esq., dated Dec. 2, 2008, pp. 1-23. cited by other. |
Primary Examiner: Haghighatian; Mina
Attorney, Agent or Firm:
RELATED APPLICATIONS
This application is based upon and claims priority of U.S. Provisional Application No. 60/180,241, filed Feb. 4, 2000, which is hereby incorporated by reference.
What is claimed is:
.[.1. A liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from 10 to about 50 mM, said composition being in a form suitable for nasal administration..].
.[.2. The liquid pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable, aqueous liquid nasal carrier..].
.[.3. The liquid pharmaceutical composition of claim 2, wherein said carrier comprises aqueous saline..].
.[.4. The liquid pharmaceutical composition of claim 1, wherein said composition is in the form of a nasal spray..].
.[.5. The liquid pharmaceutical composition of claim 4 having a viscosity of less than 0.98 cP..].
.[.6. The liquid pharmaceutical composition of claim 1, wherein the calcitonin is selected from the group consisting of salmon calcitonin, human calcitonin, porcine calcitonin and 1,7-Asu-ccl calcitonin..].
.[.7. The liquid pharmaceutical composition of claim 1, wherein the calcitonin is salmon calcitonin..].
.[.8. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 100 to about 8,000 MRC units/ml..].
.[.9. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 500 to about 4,000 MRC units/ml..].
.[.10. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 500 to about 3,000 MRC units/ml..].
.[.11. The liquid pharmaceutical composition of claim 1, wherein said calcitonin, or salt is present in an amount of from about 1,000 to about 2,500 MRC units/ml..].
.[.12. The liquid pharmaceutical composition of claim 1 having a pH of from about 3 to about 5..].
13. .[.The liquid pharmaceutical composition of claim 1.]. .Iadd.A liquid pharmaceutical composition for nasal administration comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from the group consisting of citric acid, citric acid salt and a combination thereof, wherein the combined concentration of all bioavailability enhancing agents is 10-25 mM, said composition .Iaddend.having a pH of from .[.about.]. 3.5 to .[.about.]. 3.9.
14. The liquid pharmaceutical composition of claim .[.1.]. .Iadd.13 .Iaddend.having a pH of about 3.7.
.[.15. The liquid pharmaceutical composition of claim 1 having an osmotic pressure of from about 250 to about 350 mOsm/liter..].
16. The liquid pharmaceutical composition of claim .[.1.]. .Iadd.13 .Iaddend.further containing at least 0.1% by weight of polyoxyethylene(20) sorbitan monooleate.
17. The liquid pharmaceutical composition of claim .[.1.]. .Iadd.13 .Iaddend.further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.
.[.18. A liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% polyoxyethylene(20) sorbitan monooleate..].
19. A liquid pharmaceutical composition .Iadd.for nasal administration .Iaddend.comprising about 2,200 .[.MIC.]. .Iadd.MRC .Iaddend.units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% polyoxyethylene(20) sorbitan monooleate.
.[.20. A method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering to said subject a composition as defined in claim 1 via the nasal route..].
.[.21. The method of claim 20, wherein the amount of calcitonin administered is from about 200 to about 600 MRC units..].
.[.22. A method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from 10 to about 50 mM to said composition..].
.[.23. A method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from 10 to about 50 mM to said composition prior to said administration..].
.Iadd.24. The pharmaceutical composition of claim 13, wherein said citric acid or citric acid salt concentration is 20 mM..Iaddend.
.Iadd.25. The pharmaceutical composition of claim 13, wherein said composition includes aqueous saline..Iaddend.
.Iadd.26. The pharmaceutical composition of claim 13, wherein said composition includes aqueous saline and has an osmotic pressure from 250 to 350 mOsm/liter..Iaddend.
.Iadd.27. The pharmaceutical composition of claim 13, wherein said composition has a viscosity of less than 0.98 cP..Iaddend.
.Iadd.28. The pharmaceutical composition of claim 13, wherein said calcitonin is salmon calcitonin..Iaddend.
.Iadd.29. The liquid pharmaceutical composition of claim 16, further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens..Iaddend.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to .[.an.]. intranasal pharmaceutical compositions comprising calcitonin as an active ingredient and specific concentrations of citric acid or a salt thereof as a stabilizer and absorption enhancer.
2. Description of the Related Art
Calcitonins are a class of polypeptide hormones that are used in the treatment of a variety of conditions including osteoporosis, Pagel's disease and malignant hypercalcemia. They are composed of amino acids and have been extracted from a number of sources including salmon, porcine, eel and human. Calcitonins with amino acid sequences identical to the natural forms have been produced by chemical synthesis as well as by recombinant technology.
Given their size and chemical composition, calcitonins were originally administered by subcutaneous or intramuscular injection. Other routes of administration were technically difficult because calcitonins were poorly absorbed through tissue and were readily degraded by bodily fluids. Despite these obstacles, a formulation (U.S. Pat. No. 5,759, 565) was developed that could be administered via the nasal route. The nasal formulation was designed to be stored in a multi-dose container that was stable for an extended period of time and resisted bacterial contamination. The preservative in the formulation, benzalkonium chloride, was found to enhance the absorption of salmon calcitonin. However, benzalkonium chloride was reported (P. Graf et al., Clin. Exp. Allergy 25:395-400; 1995) to aggravate .[.rhintis.]. .Iadd.rhinitis .Iaddend.medicamentosa in healthy volunteers who were given a decongestant nasal spray containing the preservative. It also had an adverse effect on nasal mucosa (H. Hallen et al., Clin. Exp. Allergy 25:401-405; 1995), Berg et al. (Laryngoscope 104:1153-1158; 1994) disclose that respiratory mucosal tissue that was exposed in vitro underwent severe morphological alterations. Benzalkonium chloride also caused significant slowing of the mucocilary transport velocity in the ex vivo frog palate test (P.C. Braga et al., J. Pharm. Pharmacol. 44:938-940; 1992).
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid and/or salt thereof in a concentration from about 10 to about 50 mM, said composition being in a form suitable for nasal administration.
The present invention also provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% TWEEN.RTM. 80.
The present invention further provides a liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benyzl alcohol, and about 0.1% TWEEN.RTM. 80.
The present invention also provides a method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering via the nasal route to said subject a liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about 10 to about 50 mM.
The present invention further provides a method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition.
The present invention also provides a method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from about 10 to about 50 mM to said composition prior to said administration.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention it has now been surprisingly found that pharmaceutical compositions can be obtained comprising a calcitonin as active ingredient which meet the high standards of stability and bioavailability required for nasal application and which are, for example, eminently suitable for use in multiple dose nasal spray applicators, i.e., applicators capable of delivering a series of individual dosages over, e.g., period of several days or weeks, by the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM as a buffering agent.
Surprisingly, it has also been found that use of citric acid or a salt thereof at increasing concentrations confers beneficial advantages in relation to the nasal absorption characteristics of calcitonin containing compositions and hence enhance calcitonin bioavailability levels consequential to nasal application. In addition, it has also been found that the use of citric acid or a salt thereof in concentrations ranging from about 10 to about 50 mM increase the stability of calcitonin containing compositions while at the same time higher concentrations of citric acid or salt thereof did not have the same stabilizing effect.
The calcitonins for use in the invention may be in free form or in pharmaceutically acceptable salt or complex form, e.g. in pharmaceutically acceptable acid addition salt form. Such salts and complexes are known and possess an equivalent degree of activity and tolerability to the free forms. Suitable acid addition salt forms for use in accordance with the invention include for example the hydrochlorides and acetates.
The above defined compositions may be applied in accordance with the invention to the nasal mucosa, e.g. either in drop or in spray form. As hereinafter described however, they are most preferably applied in spray form, i.e., in the form of finely divided droplets.
The compositions of the invention may of course also include additional ingredients, in particular components belonging to the class of conventional pharmaceutically applicable surfactants. In this connection it has in accordance with a further aspect of the present invention been found that the use of surface active agents generally in relation to the nasal application of calcitonins, in particular salmon calcitonin, may increase absorption via the nasal mucosa and hence improve obtained bioavailability rates.
Preferably, the liquid pharmaceutical calcitonin composition of the present invention contains a pharmaceutically acceptable, a liquid diluent or carrier suitable for application to the nasal mucosa, most preferably aqueous saline.
The compositions of the invention are formulated so as to permit administration via the nasal route. For this purpose they may also contain, e.g. minimum amounts of any additional ingredients or excipients desired, for example, additional preservatives or, e.g. ciliary stimulants such as caffeine.
Generally for nasal administration a mildly acid pH will be preferred. Preferably the compositions of the invention have a pH of from about 3 to 5, more preferably from about 3.5 to about 3.9 and most preferably 3.7. Adjustment of the pH is achieved by addition of an appropriate acid, such as hydrochloric acid.
The compositions of the invention should also possess an appropriate isotonicity and viscosity. Preferably they have an osmotic pressure of from about 260 to about 380 mOsm/liter. Desired viscosity for the nasal spray is preferably less than 0.98 cP. .Iadd.In one embodiment, the osmotic pressure is from 250 to 350 mOsm/liter..Iaddend.
Compositions in accordance with the present invention may also comprise a conventional surfactant, preferably a non-ionic surfactant.
When a surfactant is employed, the amount present in the compositions of the invention will vary depending on the particular surfactant chosen, the particular mode of administration (e.g. drop or spray) and the effect desired. In general, however, the amount present will be of the order of from about 0.1 mg/ml to about 10 mg/ml, preferably about 0.5 mg/ml to 5 mg/ml and most preferably about 1 mg/ml.
The amount of calcitonin to be administered in accordance with the method of the invention and hence the amount of active ingredient in the composition of the invention will, of course, depend on the particular calcitonin chosen, the condition to be treated, the desired frequency of administration and the effect desired.
As indicated in the following examples, bioavailability for calcitonins, in particular salmon calcitonin, as determined in terms of blood-plasma concentration following nasal administration in accordance with the teachings of the present invention has been found to be surprisingly high.
For nasal administration in accordance with the present invention, treatment will therefore suitably comprise administration of dosages of from about 50 to about 400 MRC units, more preferably from about 100 to about 200 MRC units at a frequency of from about once daily to about three times weekly. Conveniently dosages as aforesaid will be administered in a single application, i.e., treatment will comprise administration of single nasal dosages comprising about 50 to about 400 MRC units, preferably about 100 to about 200 MRC units, calcitonin. Alternatively such dosages may be split over a series of 2 to 4 applications taken at intervals during the day, the dosage at each application then comprising about 10 to about 200, preferably about 25 to about 100 MRC units.
The total composition quantity administered at each nasal application suitably comprises from about 0.05 to about 0.15 ml, typically about 0.1 ml. Compositions for use in accordance with the invention accordingly suitably comprise from about 150 to about 8,000, preferably from about 500 to about 4,000, more preferably from about 500 to about 3,000, yet again more preferably from about 1,000 to about 2,500, and most preferably about 2,200 MRC units of calcitonin per ml.
For the purposes of nasal administration, the compositions of the invention will preferably be put up in a container provided with means enabling application of the contained composition to the nasal mucosa, e.g. put up in a nasal applicator device. Suitable applicators are known in the art and include those adapted for administration of liquid compositions to the nasal mucosa in drop or spray form. Since dosaging with calcitonins should be as accurately controlled as possible use of spray applicators for which the administered quantity is susceptible to precise relation will generally be preferred. Suitable administrators include, e.g. atomizing devices, e.g. pump-atomizers and aerosol dispensers. In the latter case, the applicator will contain a composition in accordance with the invention together with a propellant medium suitable for use in a nasal applicator. The atomizing device will be provided with an appropriate spray adaptor allowing delivery of the contained composition to the nasal mucosa. Such devices are well known in the art.
The container, e.g. nasal applicator, may contain sufficient composition for a single nasal dosaging or for the supply of several sequential dosages, e.g. over a period of days or weeks. Quantities of individual dosages supplied will preferably be as hereinbefore defined. The stability of the compositions of the invention may be determined in conventional manner. As indicated hereinbelow, the calcitonin content of the compositions of the invention will degrade less than 50 % in 15 days at 50.degree. C. as indicated by standard analytical tests.
EXPERIMENTAL DESIGN--METHODS OF ADMINISTERING NASAL CALCITONIN
AND MEASUREMENT OF PLASMA CONCENTRATION
Female Wistar rats, weighing between 225 and 250 g are anesthetized with a combination of ketamine and xyalzine, and a cannula is inserted into the carotid artery. The cannula is fitted to a three-way valve through which blood is sampled and replaced with physiological saline containing herparin. Formulated salmon calcitonin (sCT) (5 .mu.g per 25 .mu.l) is administered intranasally through a micropipette tip that was inserted 8 mm into the rat's nostril. For single-dose studies, 5 .mu.g of sCT was administered. In multiple dose studies, sCT was administered four times in a volume of 25 .mu.l each at 0, 30, 60 and 90 minutes for a total dose of 20 .mu.g.
In single-dose studies, blood samples are collected prior to dosing and at 5, 15, 30, 60 and 120 minutes after dosing. In multiple-dose studies, blood samples are collected prior to dosing and at 30, 60, 90, 120 and 150 minutes after the administration of the first dose. Blood samples are always collected immediately before the administration of any additional .[.costs.]. .Iadd.doses.Iaddend..
Each sample (0.5 ml) of blood is collected into a heparinized 1 ml syringes and then transferred to chilled 1.5 ml polypropylene tubes containing 10 .mu.l of herparin (500 U per ml). The tubes are centrifuged at approximately 3000 rpm for 20 minutes at 2-8.degree. C. and the plasma supernatant is transferred to microcentrifuge tubes that were stored at -20.degree. C. The concentration of sCT in plasma is determined by a competitive radioimmunosaasy. Aliquots of the plasma samples and standards are incubated for 4 hours at room temperature with rabbit anti-sCT antibody. Subsequently, .sup.125I-sCT is added and incubated overnight at 2-8.degree. C. Antibody-bound .sup.125I-sCT is isolated the next day by precipitating it with normal rabbit antiserum and goat anti-rabbit antibody. Radioactivity associated with the resulting pellets is measured with a gamma counter. The concentration of sCT in plasma is inversely proportional to the amount of radioactivity that was precipitated.
The values of Cmax are determined by inspection and the values for bioavailability (relative to an intravenous injection) are calculated from the areas under the curve that were obtained from plots of plasma sCT concentration as a function of time.
EXAMPLE 1
The following study examines the effect of the concentration of citric acid on the bioavailability and plasma concentration of nasally administered salmon calcitonin. Rats were administered intranasally as described previously 20 .mu.l of rsCT (200 .mu.g/ml) in 0.85% sodium chloride, 0.1% TWEEN.RTM. 80, 0.2% phenylethyl alcohol, 0.5% benzyl alcohol and varying amounts of citric acid adjusted to pH 3.7 at t=0, 20, 60 and 90 minutes. Samples of blood were taken prior to the administration of rsCT at these time points as well as at t=120 and 150 minutes. The resulting plasma samples were analyzed for rsCT by radioimmunosassy. Maximum rsCT levels were detected at t=120 minutes. The results of this study as shown in Table 1 indicate that the bioavailability and peak concentration of rsCT was a function of the concentration of citric acid in the formulation.
TABLE-US-00001 TABLE 1 EFFECT OF THE CONCENTRATION OF CITRIC ACID ON THE BIOAVAILABILITY AND PLASMA CONCENTRATION OF SALMON CALCITONIN ADMINISTERED INTRANASALLY TO RATS Citric acid Bioavailability Maximum plasma sCT (pH 3.7) (percent .+-. sdev) (ng/ml .+-. sdev) 0 0.89 .+-. 0.19 1.10 .+-. 0.52 10 3.14 .+-. 1.77 3.66 .+-. 1.67 25 5.01 .+-. 2.34 5.11 .+-. 2.09 50 6.15 .+-. 1.31 6.05 .+-. 1.30 100 13.36 .+-. 3.38 12.98 .+-. 3.96
EXAMPLE 2
The following study examines the effect of different preservatives on the plasma concentration of nasally administered salmon calcitonin. Rats were administered intranasally as described previously 20 .mu.l of sCT (200 .mu.g/ml) in 0.85% sodium chloride, 0.1% TWEEN.RTM. 80 and a combination preservatives of either 0.2% phenylethyl alcohol and 0.5% benzyl alcohol or 0.27% methyl parabens and 0.04% proply parabens at t=0, 30, 60 and 90 minutes. The results of this study as shown in Table 2 indicate that the bioavailability and peak concentration of rsCT are not significantly affected by the addition of the different preservatives.
TABLE-US-00002 TABLE 2 EFFECT OF PRESERVATIVES ON THE AVAILABILITY AND PLASMA CONCENTRATION OF SCT ADMINISTERED INTRANASALLY TO RATS Bioavailability Maximum plasma sCT Preservatives (percent .+-. sdev) (ng/ml .+-. sdev) None 1.14 .+-. 0.87 1.24 .+-. 0.79 0.2% phenyethyl alcohol- 0.89 .+-. 0.19 1.10 .+-. 0.52 0.5% benzyl alcohol 0.27 methyl parabens- 1.08 .+-. 0.86 1.47 .+-. 1.46 0.04% propyl parabens
EXAMPLE 3
The following study examines the effect of the concentration of citric acid on the stability of salmon calcitonin stored for varying periods at a temperature of 50.degree. C. Nasal formulations containing sCT (200 .mu.g/ml), 0.25% phenylethyl alcohol, 0.5% benzyl alcohol and 0.1% TWEEN.RTM. 80 were adjusted to pH 3.7 with either HCl or the indicated amount of buffered citric acid. The formulations were stored at 50.degree. C. in sealed glass containers for the indicated amount of time and analyzed for sCT by high performance liquid chromatography. The results as shown in Table 3 indicate that in the absence of citric acid, the amount sCT in the formulation decreased steadily between 0 and 9 days after the study was begun. In the presence of citric acid (10-50 mM) the rate of disappearance of sCT decreased significantly. However, as the concentration of citric acid was further increased, the rate of sCT disappearance from vials stored at 50.degree. C. increased in proportion to the amount of buffered citric acid in the formulation.
TABLE-US-00003 TABLE 3 EFFECT OF THE CONCENTRATION OF CITRIC ACID ON THE STABILITY OF sCT STORED FOR VARYING PERIODS AT 50.degree. C. Percent sCT Recovered Days at Citric Acid (pH 3.7) 50.degree. C. 0 Mm 10 mM 20 mM 50 mM 100 mM 9 100 100 100 100 100 3 83 94 91 90 87 6 53 90 87 83 77 9 24 82 78 73 66 15 22 74 68 61 20
Copyright 2008−2012 Patents.com
